References
- Ericsson CD, Johnson PC. Safety and efficacy of loperamide. Am J Med. 1990;88:S10–S14.
- Swank KA, Wu E, Kortepeter C, et al. Adverse event detection using the FDA post-marketing drug safety surveillance system: cardiotoxicity associated with loperamide abuse and misuse. J Am Pharmacists Assoc. 2017 Mar–Apr;57(2S):S63–S67.
- Lasoff DR, Koh CH, Corbett B, et al. Loperamide trends in abuse and misuse over 13 years: 2002–2015. Pharmacotherapy. 2017;37(2):249–253.
- Stanciu CN, Gnanasegaram SA. Loperamide, the “Poor Man’s Methadone:” a brief review. J Psychoactive Drugs. 2017;49(1):18–21.
- Baker DE. Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2006;7:S11–S18.
- Daniulaityte R, Carlson R, Falck R, et al. “I just wanted to tell you that loperamide WILL WORK”: a web-based study of the extra-medical use of loperamide. Drug Alcohol Depend. 2013;130:241–244.
- FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. Safety Announcement. [ cited 2016 Jul 6].
- Hasnain M, Vieweg WVR, Howland RH, et al. Quetiapine, QTc interval prolongation, and torsades de pointes: a review of case reports. Ther Adv Psychopharmacol. 2014 Jun;4(3):130–138.
- Reynolds IJ, Gould RJ, Snyder SH. Loperamide: blockade of calcium channels as a mechanism for antidiarrheal effects. J Pharmacol Exp Ther. 1984 Dec;231(3):628–632.
- Upadhyay A, Bodar V, Malekzadegan M, et al. Loperamide induced life threatening ventricular arrhythmia. Case Rep Cardiol. 2016;2016:5040176.
- Pearlstein RA, Vaz RJ, Kang J, et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett. 2003 May 19;13(10):1829–1835.
- Mukarram O, Hindi Y, Catalasan G, et al. Loperamide induced Torsades de Pointes: a case report and review of the literature. Case Rep Med. 2016;2016:4061980.
- Namboodiri N. Bradycarda-induced Torsades de Pointes – an arrhythmia less understood. Indian Pacing Electrophysiol J. 2010;10(10):435–438.
- Marraffa JM, Holland MG, Sullivan RW, et al. Cardiac conduction disturbance after loperamide abuse. Clini Toxicol. 2014 Nov;52(9):952–957.
- Enakpene EO, Riaz IB, Shirazi FM, et al. The long QT teaser: loperamide abuse. Am J Med. 2015;128(10):1083–1086.
- Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation. 2014;129:94–125.
- Doser K, Meyer B, Nitsche V, et al. Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules). Int J Clin Pharmacol Ther. 1995;33:431–436.
- Yu JH, Kim HJ, Lee S, et al. LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. J Pharm Biomed Anal. 2004;36:421–427.